(Total Views: 1057)
Posted On: 05/27/2017 8:34:58 PM
Post# of 22868
Re: OldSaltDawg #17269
$CYTR,,just gets better and better,,,discusses buy-out candidate,,,should be multiple offers on this bad boy!
I hope your holding about 100k shares of this Fitz,,,Good news just keeps coming!!!
CytRx Corporation (NASDAQ:CYTR) Cheap Buyout Candidate
By Gene Daniel - May 26, 2017
SHARE Facebook Twitter
CytRx Corporation (NASDAQ:CYTR) made an announcement regarding soft tissue sarcomas sending shares up 100% over recent few trading sessions and alerting investors that it was time to pay attention to the news. CYTR had another nice swing yesterday finishing out a strong week regaining ground after the April spike and subsequent decline.
Recently, the company announced the U.S. Food and Drug Administration reached an agreement with CytRx on preparations for a New Drug Application submission for aldoxorubicin in soft tissue sarcomas.
CytRx Corporation (NASDAQ:CYTR) is working to fight this significant disease. Soft tissue sarcoma is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. It can arise anywhere in the body at any age. STS remains a high unmet medical need because of the difficulty in treating the more than 50 types of this aggressive cancer.
According to the American Cancer Society, in 2016 more than 12,300 new cases were diagnosed in the U.S. and approximately 5,000 Americans died from this disease. In addition, approximately 40,000 new cases and 13,000 deaths in the U.S. and Europe are part of a growing underserved market.
“We are very pleased to have achieved clarity from the FDA regarding CytRx’s soft tissue sarcoma program,” said Daniel Levitt, MD, PhD, Chief Operating Officer and Chief Medical Officer. “The FDA agreed that CytRx could use the application pathway for its filing that has been successfully used previously by the oncology drugs Abraxane®, Doxil® and Onivyde®. Our interaction with the FDA was part of a continued collaborative and productive relationship with the Agency. We look forward to providing the study reports and analysis that can lead to the approval of aldoxorubicin for the treatment of patients with soft tissue sarcomas.”
Daniel Levitt, M.D., Ph.D., Chief Operating Officer and Chief Medical Officer of CYTR, commented, “The data from both of these important clinical trials evaluating aldoxorubicin in sarcomas, along with our several other completed clinical and preclinical studies, will form the basis of our planned New Drug Application submission to the U.S. Food and Drug Administration, and we are pleased to share these more mature and detailed results in this peer-reviewed forum with the medical and scientific communities.”
Updated data relating to the trials other secondary endpoints, including objective response rate, disease control rate, overall survival, and other safety parameters were in line with what has previously been reported by CYTR and will be included in the oral presentation being given at ASCO 2017.
Aldoxorubicin is a rationally-engineered cytotoxic which combines doxorubicin, a widely used chemotherapeutic agent, with a novel linker molecule that binds directly and specifically to circulating albumin, the most abundant protein in the bloodstream. Protein-hungry tumors concentrate albumin, which facilitates the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released.
Typically, doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m2. Using this acid-sensitive linker technology, aldoxorubicin delivers greater doses of doxorubicin (3 ½ to 4 times). To date, there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 6,500 mg/m2 of doxorubicin equivalents. Aldoxorubicin is the first-ever single agent to show superiority over doxorubicin in a randomized clinical trial in first-line STS.
When you look at the price action for CytRx Corporation (NASDAQ:CYTR) you see a spike in prices as a selloff, which pushed prices back to where they began, and ending in a rally this week. The most important part of the move was the trading action this week.
They also are expanding the pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CYTR’s expertise in albumin biology for the development of a new class of anti-cancer therapies.
With volume spiking to 21M today, it would behoove investors to watch this stock as a potential buyout target.
I hope your holding about 100k shares of this Fitz,,,Good news just keeps coming!!!
CytRx Corporation (NASDAQ:CYTR) Cheap Buyout Candidate
By Gene Daniel - May 26, 2017
SHARE Facebook Twitter
CytRx Corporation (NASDAQ:CYTR) made an announcement regarding soft tissue sarcomas sending shares up 100% over recent few trading sessions and alerting investors that it was time to pay attention to the news. CYTR had another nice swing yesterday finishing out a strong week regaining ground after the April spike and subsequent decline.
Recently, the company announced the U.S. Food and Drug Administration reached an agreement with CytRx on preparations for a New Drug Application submission for aldoxorubicin in soft tissue sarcomas.
CytRx Corporation (NASDAQ:CYTR) is working to fight this significant disease. Soft tissue sarcoma is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. It can arise anywhere in the body at any age. STS remains a high unmet medical need because of the difficulty in treating the more than 50 types of this aggressive cancer.
According to the American Cancer Society, in 2016 more than 12,300 new cases were diagnosed in the U.S. and approximately 5,000 Americans died from this disease. In addition, approximately 40,000 new cases and 13,000 deaths in the U.S. and Europe are part of a growing underserved market.
“We are very pleased to have achieved clarity from the FDA regarding CytRx’s soft tissue sarcoma program,” said Daniel Levitt, MD, PhD, Chief Operating Officer and Chief Medical Officer. “The FDA agreed that CytRx could use the application pathway for its filing that has been successfully used previously by the oncology drugs Abraxane®, Doxil® and Onivyde®. Our interaction with the FDA was part of a continued collaborative and productive relationship with the Agency. We look forward to providing the study reports and analysis that can lead to the approval of aldoxorubicin for the treatment of patients with soft tissue sarcomas.”
Daniel Levitt, M.D., Ph.D., Chief Operating Officer and Chief Medical Officer of CYTR, commented, “The data from both of these important clinical trials evaluating aldoxorubicin in sarcomas, along with our several other completed clinical and preclinical studies, will form the basis of our planned New Drug Application submission to the U.S. Food and Drug Administration, and we are pleased to share these more mature and detailed results in this peer-reviewed forum with the medical and scientific communities.”
Updated data relating to the trials other secondary endpoints, including objective response rate, disease control rate, overall survival, and other safety parameters were in line with what has previously been reported by CYTR and will be included in the oral presentation being given at ASCO 2017.
Aldoxorubicin is a rationally-engineered cytotoxic which combines doxorubicin, a widely used chemotherapeutic agent, with a novel linker molecule that binds directly and specifically to circulating albumin, the most abundant protein in the bloodstream. Protein-hungry tumors concentrate albumin, which facilitates the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released.
Typically, doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m2. Using this acid-sensitive linker technology, aldoxorubicin delivers greater doses of doxorubicin (3 ½ to 4 times). To date, there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 6,500 mg/m2 of doxorubicin equivalents. Aldoxorubicin is the first-ever single agent to show superiority over doxorubicin in a randomized clinical trial in first-line STS.
When you look at the price action for CytRx Corporation (NASDAQ:CYTR) you see a spike in prices as a selloff, which pushed prices back to where they began, and ending in a rally this week. The most important part of the move was the trading action this week.
They also are expanding the pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CYTR’s expertise in albumin biology for the development of a new class of anti-cancer therapies.
With volume spiking to 21M today, it would behoove investors to watch this stock as a potential buyout target.
(2)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼
